0001213900-20-015364.txt : 20200619 0001213900-20-015364.hdr.sgml : 20200619 20200619163527 ACCESSION NUMBER: 0001213900-20-015364 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200619 DATE AS OF CHANGE: 20200619 EFFECTIVENESS DATE: 20200619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Can-Fite BioPharma Ltd. CENTRAL INDEX KEY: 0001536196 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-369370 FILM NUMBER: 20976084 BUSINESS ADDRESS: STREET 1: 10 BAREKET STREET, KIRYAT MATALON STREET 2: P.O. BOX 7537 CITY: PETACH TIKVA STATE: L3 ZIP: 4951778 BUSINESS PHONE: 972 39241114 MAIL ADDRESS: STREET 1: 10 BAREKET STREET, KIRYAT MATALON STREET 2: P.O. BOX 7537 CITY: PETACH TIKVA STATE: L3 ZIP: 4951778 D 1 primary_doc.xml X0708 D LIVE 0001536196 Can-Fite BioPharma Ltd. 10 BAREKET STREET, KIRYAT MATALON PETACH TIKVA L3 ISRAEL 4951778 972 39241114 ISRAEL None None Corporation true Ilan Cohn 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Pnina Fishman 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Executive Officer Director Motti Farbstein 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Executive Officer Guy Regev 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Abraham Sartani 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Israel Shamay 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Yaacov Goldman 10 Bareket Street, Kiryat Matalon PO Box 7537 Petach Tikva L3 ISRAEL 4951778 Director Pharmaceuticals Decline to Disclose 06b false 2020-06-10 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 3RD FLOOR NEW YORK NY NEW YORK 10022 CA CALIFORNIA FL FLORIDA NY NEW YORK false 8000002 8000002 0 The warrants and the ADSs underlying the warrants, the subject matter of this Form D, were issued in connection with an offering of (i) 3,902,440 ADSs issued in a registered direct offering, and (ii) unregistered warrants to purchase 1,951,220 ADSs. false 4 600000 0 H.C. Wainwright is also entitled to a management fee equal to 1.0% of the gross proceeds raised in the offering, a non-accountable expense allowance of $50,000 and warrants to purchase 292,683 ADSs exercisable at $2.50 per ADS for 4.5 years. 0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers. false Can-Fite BioPharma Ltd. /s/ Motti Farbstein Motti Farbstein Chief Operating and Financial Officer 2020-06-19